Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 96: 129497, 2023 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-37806499

RESUMEN

In this study, we present the discovery and pharmacological characterization of a new series of 6-piperazinyl-7-azaindoles. These compounds demonstrate potent antagonism and selectivity against the 5-HT6 receptor. Our research primarily focuses on optimizing the lead structure and investigating the structure-activity relationship (SAR) of these compounds. Our main objective is to improve their activity and selectivity against off-target receptors. Overall, our findings contribute to the advancement of novel compounds targeting the 5-HT6 receptor. Compound 29 exhibits significant promise in terms of pharmacological, physicochemical, and ADME (Absorption, Distribution, Metabolism, and Excretion) properties. Consequently, it merits thorough exploration as a potential drug candidate due to its favorable activity profile and successful outcomes in a range of in vivo experiments.


Asunto(s)
Piridinas , Antagonistas de la Serotonina , Piridinas/química , Antagonistas de la Serotonina/química , Relación Estructura-Actividad
2.
Bioorg Med Chem Lett ; 26(11): 2610-5, 2016 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-27117428

RESUMEN

A series of 1-Sulfonyl-6-Piperazinyl-7-Azaindoles, showing strong antagonistic activity to 5-HT6 receptor (5-HT6R) was synthesized and characterized. The series was optimized to reduce activity on D2 receptor. Based on the selectivity against this off-target and the analysis of the ADME-tox profile, compound 1c was selected for in vivo efficacy assessment, which demonstrated procognitive effects as shown in reversal of scopolamine induced amnesia in an elevated plus maze test in mice. Compound 3, the demethylated version of compound 1c, was profiled against a panel of 106 receptors, channels and transporters, indicating only D3 receptor as a major off-target. Compound 3 has been selected for this study over compound 1c because of the higher 5-HT6R/D2R binding ratio. These results have defined a new direction for the design of our pseudo-selective 5-HT6R antagonists.


Asunto(s)
Amnesia/tratamiento farmacológico , Indoles/farmacología , Piperazinas/farmacología , Receptores de Serotonina/metabolismo , Antagonistas de la Serotonina/farmacología , Sulfonas/farmacología , Amnesia/inducido químicamente , Animales , Conducta Animal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Indoles/síntesis química , Indoles/química , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Modelos Moleculares , Estructura Molecular , Piperazinas/síntesis química , Piperazinas/química , Escopolamina , Antagonistas de la Serotonina/síntesis química , Antagonistas de la Serotonina/química , Relación Estructura-Actividad , Sulfonas/síntesis química , Sulfonas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...